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AbstrACt
Introduction Care home residents are at increased risk 
of infections and antibiotic prescription. Reduced antibiotic 
use from fewer infections would improve quality of life. The 
Probiotics to Reduce Infections iN CarE home reSidentS 
(PRINCESS) trial aims to determine the efficacy and 
investigate mechanisms of daily probiotics on antibiotic 
use and incidence of infections in care home residents.
Methods and analysis PRINCESS is a double-blind, 
individually randomised, placebo-controlled trial that will 
assess the effect of a daily oral probiotic combination of 
Lactobacillus rhamnosus, GG (LGG) and Bifidobacterium 
animalis subsp. lactis, BB-12 (BB-12) on cumulative 
antibiotic administration days (CAADs) (primary outcome) 
for infection in up to 330 care home residents aged ≥65 
years over up to 12 months. Secondary outcomes include: 
Infection: Total number of days of antibiotic administration 
for each infection type (respiratory tract infection, urinary 
tract infection, gastrointestinal infection, unexplained fever 
and other); number, site, duration of infection; estimation 
of incidence and duration of diarrhoea and antibiotic-
associated diarrhoea; Stool microbiology: Clostridium  
difficile infection; Gram-negative Enterobacteriaceae and 
vancomycin-resistant enterococci; LGG and BB-12. Oral 
microbiology: Candida spp. Health and well-being: Self 
and/or proxy health-related quality of life EQ5D (5 L); self-
and/or proxy-reported ICEpop CAPability measure for older 
people. Hospitalisations: number and duration of all-cause 
hospital stays. Mortality: deaths. Mechanistic immunology 
outcomes: influenza vaccine efficacy (haemagglutination 
inhibition assay and antibody titres); full blood count 
and immune cell phenotypes, plasma cytokines and 
chemokines; cytokine and chemokine response in whole 
blood stimulated ex vivo by toll-like receptor 2 and 4 
agonists; monocyte and neutrophil phagocytosis of 
Escherichia coli; serum vitamin D.
Ethics and dissemination Ethics approval is from 
the Wales Research Ethics Committee 3. Findings will 
be disseminated through peer-reviewed journals and 
conferences; results will be of interest to patient and policy 
stakeholders.
trial registration number ISRCTN16392920; Pre-results.
IntroduCtIon
Care home residents are at increased risk 
of infections due to weakened immunity, 
close-proximity living and multimorbidity 
and are prescribed antibiotics for an average 
of almost 20 days each year, far more than 
the general population.1 2 High antibiotic use 
increases the risk of colonisation and infection 
with antimicrobial-resistant (AMR) organisms 
that may then cycle within care homes and 
spread between hospitals and community. 
Infections in care home residents cost the 
strengths and limitations of this study
 ► Relevant information on an under-researched popu-
lation in a growing sector of care.
 ► Option for participants to opt out of aspects of sam-
ple collections, potentially enhancing recruitment 
and thus generalisability.
 ► Data will be collected prospectively on a weekly 
basis for each trial participant by blinded research 
nurses visiting care homes.
 ► Recruiting to our target will be a challenge especial-
ly as we will approach consultees for participants 
who lack capacity to consent for themselves.
 ► Recent antimicrobial stewardship guidance specifi-
cally for long-term care facilities could result in low-
er antibiotic prescribing rates during the trial.
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NHS >£54 million/year in hospitalisation alone3 and are 
the most common reason for residents to be hospitalised. 
AMR Gram-negative septicaemia and AMR urinary tract 
infection (UTI) are on the increase in the community, 
especially among older people.4 5 Recent consumption 
of antibiotics is the greatest risk factor for carriage and 
infection with AMR bacteria even after controlling for 
age, comorbidity and other risk factors.6 7 AMR infections 
are generally more serious and are associated with longer 
hospital stays, increased costs and increased risk of poor 
outcomes including death, particularly in older people.8 
Evidence-based interventions are needed to improve 
the quality of life through reducing the incidence of 
common infections and antibiotic use.9 Other than vacci-
nation and hygiene methods, there are few interventions 
proven to prevent infection in care homes, and even 
so-called ‘minor’ infections can have an important nega-
tive impact on health, well-being and dignity, especially 
for older, frail people.
Probiotics are defined by the WHO as ‘live microor-
ganisms which when administered in adequate amounts 
confer a health benefit to the host’.10 They may prevent 
infection by blocking pathogenic colonisation and 
enhancing gut-immune interaction, with influence on 
mucosal and systemic immunity, leading to enhanced 
natural killer  cell activity and vaccine response11 in older 
people.12 13 A systematic review and meta-analysis found 
that probiotics reduced the risk of upper respiratory tract 
infections (URTIs) and reduced antibiotic prescribing 
in adults and that side effects were minor.14 However, 
the review noted poor allocation concealment in several 
studies and heterogeneity in findings and recommended 
that future randomised controlled trials (RCTs) should 
‘focus on older people’. Meta-analysis indicates that probi-
otics can reduce antibiotic-associated diarrhoea (AAD), 
but more research is needed to determine which probi-
otics are associated with greatest efficacy and for which 
patients receiving which specific antibiotics.15 Probiotics 
may also reduce AMR colonisation,14 which could be 
important as most UTIs arise from autoinoculation with 
gut organisms.
Effects of probiotics are thought to vary by strain due 
to differing resistance to gastric acid and bile, ability to 
colonise mucosa and susceptibility to antibiotics. Lactoba-
cillus rhamnosus, GG (LGG) is the most studied probiotic, 
including in elderly populations, and has been found to 
be safe. In a meta-analysis of RCTs involving 1805 chil-
dren, LGG reduced the risk of otitis media, URTI and 
antibiotic use.16 LGG may act as an immune adjuvant to 
influenza vaccination17 and benefit oral health.18 Many 
studies have utilised several strains of probiotic simultane-
ously (which may increase efficacy due to differing modes 
of action), and LGG and Bifidobacterium animalis subsp. 
lactis, BB-12 (BB-12) have been included in the same 
probiotic formulation.19 20 The combination probiotic 
reduced severity and duration of URTIs in 231 college 
students.21 The combination probiotic, and BB-12 alone, 
have been shown to reduce URTIs and otitis media in 
infants22 23 and to reduce symptoms of irritable bowel 
syndrome and stabilise bowel microbiota in adults.24 
However, neither probiotic strain has been evaluated 
primarily in care home residents. Although probiotics are 
effective in preventing AAD,15 25 evidence is lacking on 
the prevention of all-cause common infections and anti-
biotic prescribing in care homes.
MEthods And AnAlysIs
objectives
PRINCESS aims to evaluate effectiveness of daily admin-
istration of a combination of two probiotics (LGG and 
BB-12) on total days on antibiotics for infections, inci-
dence and severity of infections, and on a range of 
secondary and related mechanistic outcomes.
design and setting
A double-blind, individually randomised placebo-con-
trolled trial. An internal pilot will assess care home 
recruitment, data collection, study product adminis-
tration and sampling procedures. Participants are care 
home residents in approximately 20 care homes in Wales 
and England.
Participants
Inclusion criteria
 ► Currently living in a care home setting (residential, 
nursing or mixed).
 ► Willing and able to give informed consent for partici-
pation in the trial OR if the participant lacks capacity, 
a consultee willing to complete a consultee declara-
tion form for participation on their behalf.
 ► Aged 65 years or older.
Exclusion criteria
 ► Known to be immunocompromised (requiring 
immune-suppressants, long-term, high-dose, oral, 
intramuscular or intravenous steroids).
 ► Currently taking regular probiotics and is not willing 
to adapt to trial protocol.
 ► Currently participating in a clinical trial of an inves-
tigational medicinal product (CTIMP) or has been a 
participant in a CTIMP in the last 30 days.
 ► A temporary care home resident (ie, less than 1 month 
of planned transitional/respite residential care).
 ► Death is thought to be imminent.
 ► Is lactose intolerant.
Informed consent
Informed consent or a consultee declaration (see below) 
will be obtained prior to any trial procedures. Where there 
are concerns that a resident may have impaired mental 
capacity, a mental capacity assessment will be undertaken 
by a qualified research nurse (RN) in accordance with the 
Mental Capacity Act 2005. Eligible residents may partici-
pate in the trial even if they (or their consultee) prefer 
to opt out from providing blood and/or stool and/or 
saliva samples. Residents who provide informed consent 
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at trial entry will be asked to agree to remain in the study 
in the event of a loss of capacity. The PRINCESS RNs will 
be trained in how to assess capacity, and trial participants 
will be (re)assessed regularly. Trial participant’s general 
practitioner (GP) will be informed of their participation 
in the PRINCESS trial.
Residents lacking capacity
Where a resident lacks capacity to provide consent for 
themselves, a family member or friend will be consulted 
and will act as their ‘consultee’. If a consultee who has an 
unpaid or non-professional role in care cannot be identi-
fied, or is not willing to act, a nominated consultee will be 
appointed and consulted prior to including the resident 
in the trial. If a consultee themselves loses capacity or dies 
during the trial period, an alternative family member or 
friend will be contacted to act as consultee and a new 
consultee declaration form will be completed. If there 
is no one to represent the resident concerning the trial, 
they will be ineligible or withdrawn if already recruited. If 
agreement for the resident to participate is provided by a 
consultee due to lack of capacity and they regain capacity 
during the trial, the participant will be fully informed 
and consent to remain in the trial will be sought from the 
participant themselves. If a consultee is required and they 
cannot attend a face-to-face interview, the above docu-
ments may be sent from and returned to the care homes 
by post.
Verbal consent/declaration
If a resident or a consultee cannot read or provide hand-
written signatures on the consent/declaration form, 
verbal consent/agreement will be taken. In such cases, a 
delegated individual will read the trial information sheet 
to them and discuss the trial to ensure understanding. 
A member of the research team will witness, sign and 
date the consent/declaration form to confirm that valid 
consent or a consultee declaration has been given.
Withdrawal
Participants may withdraw/be withdrawn from the trial at 
any time for any reason without prejudice to future care, 
and with no obligation to give a reason, and will be given 
an option as to the level of withdrawal of data.
randomisation
Participants will be remotely randomised using an online 
system developed and hosted by the University of Oxford 
Primary Care Clinical Trials Unit (Sortition). Partici-
pants will be randomised to either probiotic or placebo 
in a 1:1 ratio using minimisation. Allocations will be 
balanced by care home and resident gender. A random 
component, set at 80%, will maintain integrity of the allo-
cation process. As PRINCESS is a double-blind trial, the 
participants, care home staff, treating clinicians and trial 
team (including the trial statistician and RNs conducting 
all assessments) will be unaware of the group to which 
the participant has been allocated for the duration of 
the trial. If unblinding is needed, the procedure will be 
documented and performed by the independent statis-
tician, and as a back-up the Centre for Trials Research 
(CTR) pharmacovigilance and safety team will also be 
trained to perform this function.
Intervention
Participants will be asked to take an oral dose of probi-
otic (LGG and BB-12) or a matched placebo (containing 
maltodextrin, microcrystalline cellulose, magnesium 
stearate and silicon dioxide) as a capsule once daily for 
up to 12 months. The manufacturer of study products 
is Chr. Hansen A/S, Bøge Alle 10–12, 2970 Hørsholm, 
Denmark. The dates of manufacture of study products 
are December 2015 (total cell count per capsule 1.6×1010) 
and March 2017 (total cell count per capsule 1.3×1010).
The probiotic or placebo (referred to as study product) 
will be administered by the resident’s normal caregiver. 
The preferred route of administration will be as follows:
1. The capsule swallowed whole with water.
2. Capsule will be emptied into a small amount of cold or 
lukewarm liquid and swallowed.
3. Capsule contents will be sprinkled onto cold or luke-
warm (not hot) food and eaten.
The capsules will be suitable for vegans, are Halal 
and Kosher (Kosher dairy excluding Passover), will not 
contain any genetically modified organisms or raw mate-
rials and allergen labelling will not be required. The 
capsules will contain lactose. They will be stable at room 
temperature for 2 years and temperature monitoring will 
not be required for short-term (eg, 1 month) storage. 
Participants admitted to hospital will not be expected to 
continue taking study product during their hospital stay. 
Data regarding participants’ adherence to study product 
will be collected from several sources including medica-
tion administration record sheets and regular capsule 
counts (of unused study product). Stool culture will also 
be used to determine the presence of probiotic organ-
isms in the bowel of participants who provide consent for 
these samples at baseline, 3 and up to 12 months. This will 
give an indication of adherence, survival of the probiotic 
in the large bowel and potential contamination in the 
placebo arm. Study product will be continued even when 
on antibiotics and other medications.
outcomes
Primary outcome
Cumulative systemic antibiotic administration 
days (CAAD) for all-cause, acute infections; total number 
of days of systemic antibiotic administration as recorded 
in care home medical records and discharge summaries 
if the participant is admitted to hospital, collected by the 
RNs.
Secondary outcomes
Infection
 ► Total number of days of antibiotic administration for 
each infection type as recorded in care home medical 
records (collected by RNs).
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 ► Number, site, duration (mean and cumulative) of 
infection, as recorded in care home medical records 
(collected by RNs).
 ► Estimation of incidence and duration of diarrhoea 
when taking (and not taking) oral antibiotic treat-
ment and AAD (question asked by RNs).*
 ► Stool sample laboratory analysis
 – Prevalence of Clostridium difficile** infection.
 – Culture and antibiotic sensitivity of Gram-negative 
Enterobacteriaceae and vancomycin-resistant 
enterococci. 
 – Levels of LGG and BB-12.
Oral microbiology
 ► Semiquantitative analysis of oral rinse or saliva samples 
for Candida spp.
Health and well-being
 ► Self and/or proxy-reported health-related quality of 
life measurement EQ-5D (5 L).
 ► Self-and/or proxy-reported ICEpop CAPability 
measure for Older people (ICECAP-O).
Hospitalisations
 ► Number and duration of hospital stays for all-cause 
hospitalisation (as recorded in care home records and 
discharge summaries, collected by RNs).
Mortality
 ► Deaths (from care home records, collected by RNs).
Mechanistic immunology outcomes
 ► Influenza vaccine efficacy (haemagglutination inhibi-
tion assay and antibody titres).
 ► Full blood count.
 ► Immune cell phenotypes, plasma cytokine and 
chemokine concentrations, cytokine and chemokine 
responses in whole blood samples stimulated ex vivo 
by toll-like receptor 2 and 4 agonists and leucocyte 
phagocytosis of Escherichia  coli.
Tertiary outcomes
Level of serum vitamin D and AMR colonisation within 
stool sample.
*Diarrhoea is defined as: 'the abnormal passing of 
loose or liquid stools, with increased frequency and/or 
increased volume' (National Institute for Health and 
Care Excellence (NICE) Clinical Knowledge Summa-
ries). However, the norm for the participant will also 
considered when collecting this information as care 
home residents often have loose stools as a result of over-
flow or aperient use rather than an infective cause. Stool 
charts are kept in care homes that usually record stool 
consistency based on the Bristol Stool Chart, and our 
RNs will have access to these charts. We have trained our 
RNs to record the presence of loose stools. AAD will be 
defined as diarrhoea occurring following administration 
of antibiotics and up to 8 weeks after stopping antibiotic 
treatment.2
**We will look at the presence of C. difficile in the stool 
as a risk factor for further disease, which could be influ-
enced by probiotics.
sample size
Primary outcome
The original target for the PRINCESS trial was to 
randomise 330 participants from around 20 care homes 
in Wales and England for 90% power at the 5% level 
to demonstrate a 10% relative reduction in CAADs 
(assuming an average CAAD of 17.4 days and an abso-
lute reduction in the probiotic arm to 15.6 days per resi-
dent-year). We consider that a 10% reduction is feasible 
and would be clinically important.
This sample size accounted for 30% of participants 
being lost to follow-up due to withdrawal or death during 
the study.
An interim assessment (to determine if we met the 
Stop/Go contractual criteria) of primary outcome ascer-
tainment revealed that the mean percentage of days for 
which there are valid antibiotic administration data (ie, 
either no antibiotics administered or the number of days 
on which antibiotics have been administered in each 
week) is 77.4% or 283 days out of a possible 365 on average. 
This percentage varies depending on the length of time 
participants have been in the study. However, it remains 
high for participants in the study for over 6 months and 
does not consider other data sources that might be used 
(eg, hospital discharge summaries, medication adminis-
tration records). This is likely therefore to underestimate 
availability of primary outcome data, but nevertheless is 
a more accurate reflection of the likely level of follow-up 
when compared with our original assumption.
Given slower than anticipated recruitment, and 
this new information regarding the trade-off between 
numbers of participants required and average length of 
follow-up, we will aim to randomise between 258 and 270 
participants. Assuming a mean number of days for which 
primary outcome data will be available (ie, accounting for 
follow-up time and missing data) of approximately 250 
days, this will provide at least 82% power to detect a 10% 
relative reduction in CAAD.
Secondary mechanistic outcomes
Previous research has found a 40% prevalence of multi-
drug-resistant E. coli in faecal samples of UK nursing 
home residents3 and a 37% prevalence of oral candida in 
hospitalised elderly patients.26 A meta-analysis of six trials 
of probiotics in critically ill patients reported that probi-
otics reduced colonisation with multidrug-resistant gram 
negatives (OR=0.39, 95% CI 0.16 to 0.95).27 Despite high 
prevalence of AMR colonisation in care home residents, 
few studies have measured the effect of probiotics on this 
outcome. Hatakka et al found that probiotics reduced 
the risk of oral candida in 276 older people by 75% 
(OR=0.25, 95% CI 0.10 to 0.65).28 Stool and saliva samples 
at 6 to 12 months will provide 90% power at the 5% level 
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to detect a 19% absolute reduction of AMR bacteria and 
oral candida, assuming a 30% drop-out rate.
study procedures
The study scheme is presented in figure 1.
Data collection
Data collection is undertaken exclusively by RNs (all 
fully registered with the UK Nursing and Midwifery 
Council) who are employed by either Cardiff University 
or the University of Oxford, or by local NHS Research 
Organisations. Care home staff were not involved in data 
collection.
Data management
All data collection will be by electronic data capture using 
a bespoke Structured Query Language (SQL) database 
developed by the CTR, and paper copies of all case report 
forms (CRFs) will be available if needed.
Questionnaires
EQ-5D (health utility) and ICECAP-O (well-being) ques-
tionnaires will be collected at baseline, 3 months and at 
up to 12 months.
Diary
Weekly diaries will be collated by the RNs for each partici-
pant which will include: level of dose taken of study product 
and method of ingestion and on what days; and if, during 
the past week, there have been any signs of infection; use 
of antibiotics; any diarrhoea; hospitalisation; any serious 
or trial-related adverse event. If the answer to any of the 
prompt questions is ‘yes’, further information is collected as 
to which days these covered, and if antibiotics were taken, 
the route of antibiotic administration is also recorded (eg, 
IV, PO, topical). Information received about antibiotic use 
while in hospital is captured by the RNs.
Mechanistic study samples
Full blood count and vitamin D will be measured at base-
line in all participants who provide consent or whose 
consultee provides agreement for the blood test (vitamin 
D enhances anti-infective activities of macrophages). In 
a subgroup of up to 150 trial participants, additional 
samples will be taken at baseline and at up to 12 months 
to evaluate immune cell phenotypes, plasma cytokine 
and chemokine concentrations, cytokine and chemokine 
responses in whole blood samples stimulated ex vivo by 
toll-like receptor 2 and 4 agonists, and leucocyte phago-
cytosis of E. coli. A subset of patients who have been on 
the study product for at least 2 months will be asked to 
provide a blood sample on the day of (or up to 10 days 
prior to) and approximately 4 weeks after they receive 
their routine seasonal influenza vaccination. We will 
evaluate influenza vaccine efficacy by haemagglutination 
inhibition assay and antibody titres. Each participant will 
be asked to provide stool and saliva samples at baseline, 
3 months and up to 12 months to evaluate the gut and oral 
microbiology. Results will be compared between those 
on the probiotic and placebo at the end of the study. If 
participants prefer not to provide any, or all, of the trial 
samples detailed above, this will not prevent their entry 
to the trial.
Confidentiality
All data will be stored confidentially on password-protected 
servers maintained on the Cardiff University Network.
statistical analysis
There will not be any interim analyses. The analysis and 
reporting of the results will follow the Consolidated Stan-
dards of Reporting Trial guidelines.29
Primary and secondary outcomes analysis
The primary analysis will be based on a modified inten-
tion-to-treat population, with participants and their 
observed data included in the arm to which they were 
originally randomised (regardless of any postrandomi-
sation deviations). The differences in the mean CAAD 
will be compared between arms using a two-level Poisson 
regression model, with participants nested within care 
homes. The CAAD count will be included as the outcome, 
participant gender will be included as a fixed effect (as it 
was an additional balancing variable at randomisation) 
and the length of time that participants were observed 
will be included as an offset variable. Negative binomial 
regression will be used in the presence of overdispersed 
count data.
The primary analysis will be by intention-to-treat and 
will consist of a between-group comparison of mean 
CAAD using Poisson regression. As the randomisation 
will be stratified by care home, the regression model will 
control for the care home a participant was recruited 
from. Negative binomial regression will be used in the 
presence of overdispersed count data. For secondary 
outcomes, depending on the type of data, a mixture of 
two-level Poisson, linear, logistic and Cox models will be 
used to appropriately compare trial arms with respect to 
rates, means, proportions and time to events.
Adherence-adjusted analysis
RNs will record day-to-day study product use on a weekly 
case report form. Thus, adherence data will be ascer-
tained primarily from carer reports. We will perform 
adherence-adjusted analyses, deriving estimates of treat-
ment efficacy that maintain a comparison of groups as 
randomised, using structural mean models. Depending 
on the type of outcome, these models will be fitted using 
the generalised methods of moments framework (for 
generalised linear models) or two-stage least squares 
procedure (for linear models).30 Two definitions of 
adherence will be investigated—these are based on the 
ABC taxonomy described by Vrijens et al.31
1. Initiation: A participant will have been deemed as hav-
ing initiated their study product if the data collected 
on the weekly records indicates they used it at least 
once during the follow-up period.
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Figure 1 Scheme of study procedures and data collection for the PRINCESS trial. *The follow-up schedule will depend on 
the length of time that a participant has been in the study. Where possible, participants will have a baseline assessment and 
follow-up at 3 and 12 months. Due to time limitations, some participants may have a truncated follow-up and will receive either 
a baseline assessment and 3-month follow-up or a baseline assessment, 3-month follow-up and a second follow-up between 
6 and 10 months postrandomisation. Infection, antibiotic use, adverse events and study product use will be recorded at regular 
intervals by the RN from care home notes for up to 12 months postrandomisation or until 31 October 2018, whichever is sooner.
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2. Implementation: Percentage of days that participants 
took their study product as indicated (with those not 
initiating set at zero).
Missing data adjustments
Given our proposed intensive ascertainment processes, 
missing data are likely to be minimal for participants who 
remain in the trial for the full duration. Where missing 
data are likely to occur, it will most likely be due to partic-
ipant dropout, with reasons for dropout falling into two 
broad categories, withdrawal from the trial and death. We 
will investigate the sensitivity of our findings to various 
missing data mechanisms, exploring the extent to which 
withdrawal (and within this health-related withdrawal and 
withdrawal for other reasons) and death (and within this 
infection-related death and death due to other causes) 
require different adjustment methods.
Subgroup analysis
Subgroup analyses will be performed to explore differen-
tial treatment effects on the primary outcome measure. 
Interaction terms will be fitted between trial arm and the 
following measures thought to be correlated with the 
primary outcomes. These include the following:
 ► Gender.
 ► Baseline capacity to consent to the trial.
 ► Clinical frailty scale at baseline (grouped as very fit 
to managing well/vulnerable to moderately frail/
severely frail to terminally ill).
Mechanism analysis
Data from the mechanistic studies will be compared 
between groups controlling for value at study entry. 
Further statistical modelling will explore the causal 
mechanisms by which the probiotic may have an effect. 
Mediation analyses will explore the effect of exposure to 
probiotics on CAAD and cumulative number of infection 
days and whether this is mediated through an effect on 
antimicrobial resistance. These analyses will be performed 
using G-computation.32 33
A detailed Statistical Analysis Plan (SAP) will be written 
and signed prior to any analysis commencing.
trial steering Committee and Independent data Monitoring 
Committee
An independent Trial Steering Committee (TSC) will be 
established to provide oversight of the PRINCESS trial. 
This will include at least an independent chairperson, 
two independent members and a patient representative. 
An Independent Data Monitoring Committee (IDMC) 
will convene at least annually to provide oversight of 
all matters relating to patient safety and data quality. 
Members will be required to sign up to the remit and 
conditions as set out in the TSC and IDMC Charters.
Adverse event reporting
non-serious adverse events (AEs)
Non-serious AEs with the causality classification of prob-
ably or definitely related to the study product (such as 
gastrointestinal symptoms or ingredient-related allergic 
reaction) or study procedures (such as a haematoma 
at the site of venepuncture for a study sample) will be 
collected as part of routine follow-up (recorded by the 
RN as part of the weekly review) from the time of consent 
until the end of the trial. Other non-serious AEs will not be 
collected. The principal investigator/care home staff will 
manage AEs according to routine care home procedures.
Serious adverse events
Serious adverse events (SAEs) will be collected as part 
of routine follow-up (from the time of consent until the 
end of the trial). SAEs will be discussed (in person, by 
phone, or by email) by the RN with a second delegated 
assessor (eg, another RN or a clinician involved in the 
PRINCESS study) to confirm the causality classification 
(definitely, probably, possibly, unlikely, unrelated). The 
details of the second assessment will be recorded as part 
of the weekly review. Where there is a difference in clas-
sification between the two assessors, the highest category 
of causality (most likely to be related) will be selected. 
If either reviewer classifies the SAE as either definitely or 
probably  related to study procedure or study intervention, 
a Serious Adverse Reaction (SAR) form will be completed 
and the SAR will be assessed for expectedness by the chief 
investigator or delegated clinical reviewer.
 ► If the event is classified as definitely or probably 
related to the study procedure and is unexpected, it will 
be reported to sponsor, Research Ethics Committee 
(REC) and the IDMC.
 ► If the event is classified as definitely or probably 
related to the study intervention, is unexpected and 
unblinding shows that the participant is allocated 
to the intervention arm, it will be reported to the 
sponsor, REC and the IDMC.
 ► If the event is classified as definitely or probably 
related to the study intervention, is unexpected and 
unblinding shows that the participant is allocated to 
the placebo arm, and the clinical reviewer believes the 
SAR to be an allergic reaction to the excipient, it will 
be reported to the sponsor, REC and the IDMC.
EthICs And dIssEMInAtIon
Ethical approval
All trial participants or their consultee will give informed 
consent or consultee declaration before taking part (see 
earlier).
The following substantial amendments were made to 
the trial and were communicated to all trial sites:
1. Changes to the protocol.
2. Trial poster for care homes.
3. Addition of a secondary outcome (incidence and 
duration of diarrhoea).
4. Letter to consultee of a trial participant who initially 
had capacity, but who lost capacity.
5. Consent procedure for nominated consultee.
6. Shortened follow-up and clarification of objective 
and outcome terminologies.
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dissemination
The final report will be prepared for the National Insti-
tute of Health Research (NIHR) Journal series. The main 
trial results will be submitted for publication in a first 
rank, high-impact, international, peer-reviewed general 
medical journal. Other results, including secondary and 
mechanistic analyses, will also be submitted to high-im-
pact, peer-reviewed scientific journals. Results will also 
be presented at national and international meetings, 
including general medical, geriatric medicine and 
primary care meetings. We will also disseminate our 
results to the Department of Health, NHS bodies in the 
four UK countries, NICE, NHS Evidence, Age UK and 
other patient and policy stakeholders. Dissemination of 
our findings will have two main objectives:
1. To use any recognised benefits of the interventions re-
sulting from this study and further evaluation.
2. To enhance academic collaborations linking relevant 
research areas in this field and identify further areas 
where research could be effectively directed.
We will hold panel discussion events inviting academics, 
stakeholders, members of the public and service users 
at the end of the project to inform further course of 
action, which will depend on our findings. Our Involving 
People contributors will lead on developing a dissemina-
tion strategy most appropriate for care home staff, care 
home residents and their families.
dIsCussIon
Interventions that reduce antibiotic use, incidence and 
severity of infections and antimicrobial resistance in care 
home residents have the potential to improve health, 
save costs and help preserve the efficacy of existing anti-
biotics. Currently, infections are the the most common 
reason for the hospitalisation of care home residents, 
and at a time when we are experiencing AMR because of 
antibiotic overuse, there is urgent need to investigate safe 
and effective alternatives for preventing infections and 
enhancing immunity. Probiotics are cheap, safe and have 
minimal side effects, and there are plausible mechanisms 
by which they may enhance resilience against infection in 
care home residents and thus reduce antibiotic use. This 
could lead in turn to containing antibiotic resistance and 
reduce the risk of side effects from antibiotics. However, 
empirical evidence is needed to determine whether care 
home residents should take probiotics to reduce antibi-
otic use and prevent infection. This study will also add to 
the evidence base about the influence of taking probiotic 
on measures of immunity, including response to seasonal 
influenza vaccine. The PRINCESS trial will determine the 
efficacy of probiotics to reduce antibiotic use and infec-
tions in care home residents with potential benefits to the 
community and healthcare delivery. A lay summary of the 
results and links to publications will be made available on 
the University trial website and will be given to the care 
home, the participant and/or their consultee.
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